Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA
暂无分享,去创建一个
R. Schlenk | A. Ganser | K. Götze | D. Nowak | W. Hofmann | C. Haferlach | M. Lübbert | U. Germing | A. Giagounidis | A. Fabarius | U. Platzbecker | F. Nolte | M. Mossner | V. Nowak | J. Obländer | D. Haase | A. Letsch | G. Bug | S. Fey | J. Jann | I. Palme | J. Pressler | Christina Xanthopoulos
[1] O. Fuchs. Recent Developments in Myelodysplastic Syndromes , 2019 .
[2] A. Trumpp,et al. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. , 2016, Blood.
[3] R. Schlenk,et al. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5) , 2016, Leukemia.
[4] Martin C. Müller,et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML , 2015, Annals of Hematology.
[5] Peter Gill,et al. Genotyping and interpretation of STR-DNA: Low-template, mixtures and database matches-Twenty years of research and development. , 2015, Forensic science international. Genetics.
[6] G. Mufti,et al. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS) , 2015, Leukemia.
[7] R. Bejar,et al. Recent developments in myelodysplastic syndromes. , 2014, Blood.
[8] A. Trumpp,et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. , 2014, Cell stem cell.
[9] F. Solé,et al. Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? , 2012, Leukemia research.
[10] J M Bienvenue,et al. Sample-to-Result STR Genotyping Systems: Potential and Status. , 2012, Forensic science review.
[11] C. Berthou,et al. Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients , 2012, Leukemia.
[12] R. Tubbs,et al. Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: a prospective analysis of 433 cases. , 2011, American journal of clinical pathology.
[13] Xavier Robin,et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.
[14] L. Trümper,et al. FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients. , 2010, Leukemia research.
[15] E. Thiel,et al. Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500K SNP arrays identifies significant regions of deletion and uniparental disomy. , 2009, Experimental hematology.
[16] J. Maciejewski,et al. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. , 2008, Cancer genetics and cytogenetics.
[17] A. Tchirkov,et al. Gene dosage methods as diagnostic tools for the identification of chromosome abnormalities. , 2008, Pathologie-biologie.
[18] C. O'keefe,et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. , 2008, Blood.
[19] Thomas H Müller,et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.
[20] K. Halling,et al. Fluorescence in situ hybridization in diagnostic cytology. , 2007, Human pathology.
[21] B. Johansson,et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes , 2007, Genes, chromosomes & cancer.
[22] M. McDevitt,et al. Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of leukemia patients: implications for occupational surveillance. , 2007, Mutation research.
[23] I. Yaniv,et al. Assessing quantitative chimerism longitudinally: technical considerations, clinical applications and routine feasibility , 2007, Bone Marrow Transplantation.
[24] C. O'keefe,et al. High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. , 2007, Experimental hematology.
[25] R. Weksberg,et al. A method for accurate detection of genomic microdeletions using real-time quantitative PCR , 2005, BMC Genomics.
[26] A. Kasprzyk,et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. , 2002, Blood.
[27] B. Cheson,et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.
[28] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[29] Jo-Anne Bright,et al. Characterising stutter in forensic STR multiplexes. , 2012, Forensic science international. Genetics.
[30] A. Cuneo,et al. Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. , 2001, Haematologica.
[31] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .
[32] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.